Found 460 results in Expert Content

In this webinar, participants will learn about a comprehensive strategy to streamline development and derisk clinical studies. Experts will focus on the importance of physiologically based pharmacokinetic (PBPK) modeling, formulation, and technology expertise while sparing API and managing funding and timeline challenges.

Nasal development is an attractive option but can be difficult, requiring expertise to overcome formulation challenges, and to navigate the complexities of drug/device combination products to optimize drug delivery.

Summary: This executive summary showcases critical considerations and strategies for dosing lipid formulations in preclinical models, along with an overview of the regulatory and technical nuances involved in advancing preclinical lipid-based formulations (LBF) to viable clinical dosage forms.

Join our expert-led panel to explore innovative formulation strategies, the diverse mechanisms of action, preclinical and clinical considerations, as well as encapsulation techniques, and more.

Micronization, the process of reducing the size of active pharmaceutical ingredient (API) particles to micrometer scale, plays a critical role in various pharmaceutical applications and analyzing micronized particles is essential to ensure their quality and performance.

Summary: Softgels are ideal for LBF delivery and are compatible with various formulations. Innovations like delayed release and plant-based capsules enhance drug delivery. LBFs with a Quality-by-Design approach offer an efficient route to market for complex drugs.

Summary: Originally published in Inhalation magazine, this article discusses how nasal powder formulations represent a significant stride in drug delivery innovation. With drug developers and approvers evolving to address the unique considerations of nasal drug delivery, nasal powders offer a robust and adaptable platform in the pharmaceutical landscape.

Summary: Catalent President and CEO Alessandro Maselli sits down with Endpoints News founder John Carroll to discuss the evolving role of CDMOs and what’s next for Catalent as it progresses with its shift from public to private ownership under its previously announced transaction with Novo Holdings.

Learn how softgel capsules have advanced drug delivery by encapsulating a variety of active pharmaceutical ingredients (APIs).

Summary: In this interview with Pharmtech, Karunakar Sukuru, Global Vice President, Rx Product Development, Pharma and Consumer Health, Catalent shares his thoughts on the key benefits of Lipid based formulations (LBF.)